In the News

Press Releases and Media Coverage

April 14, 2025

Pheast Therapeutics Announces First Patient Treated in Phase 1 Clinical Trial of PHST001 for Patients with Advanced Solid Tumors

Read Article
February 18, 2025

Pheast Appoints Dr. Raphaƫl Rousseau as Chief Medical Officer

Read Article
November 7, 2024

Pheast Presents New Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor, at SITC 2024

Read Article
May 13, 2024

Pheast Unveils First Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor

Read Article
April 26, 2022

Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancer

Read Article